Company Overview of Crescendo Bioscience, Inc.
Crescendo Bioscience, Inc., a molecular diagnostics company, is engaged in developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases in the United States. It offers Vectra DA, a multi-biomarker blood test for RA disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score to help physicians make more informed treatment decisions. The company was founded in 2002 and is headquartered in South San Francisco, California. Crescendo Bioscience, Inc. is a subsidiary of Myriad Genetics, Inc.
341 Oyster Point Boulevard
South San Francisco, CA 94080
Founded in 2002
Key Executives for Crescendo Bioscience, Inc.
Co-Founder and Scientific Advisor
Senior Vice President of Medical Affairs
Compensation as of Fiscal Year 2014.
Crescendo Bioscience, Inc. Key Developments
Myriad Genetics Appoints Bernard Tobin as President of Crescendo Bioscience, Effective January 5, 2015
Dec 22 14
Myriad Genetics, Inc. announced the appointment of Bernard Tobin as president of Crescendo Bioscience, effective January 5, 2015. He will succeed William Hagstrom, who has chosen to pursue new start-up business and social venture opportunities. Tobin will report to Peter Meldrum, president and CEO, Myriad Genetics. Hagstrom will remain with the company until January 2, 2015 to ensure a smooth transition in leadership. Tobin has held several senior positions at Amgen over the past seven years, including Executive Director of National Accounts, General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence.
Crescendo Bioscience Presents New Clinical Data on Vectra(R) DA at ACR
Nov 19 14
Crescendo Bioscience presented new data that showed Vectra(R) DA is a better predictor of radiographic progression over two years than other tests used to assess risk of joint damage in rheumatoid arthritis (RA), such as C-reactive protein (CRP). The oral presentation was featured at the 2014 American College of Rheumatology (ACR) Annual Meeting in Boston, Massachusetts. The study included 143 patients with RA who had received a stable treatment and were enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) registry in the United States. Patients were evaluated at their initial visit in the BRASS registry for the Vectra DA score and conventional measures of disease activity, including CRP, DAS28-CRP, CDAI, SDAI and RAPID3, and provided X-rays of hands and wrists at approximately the initial visit and two years later. These data were used to assess the relationship between disease activity and the amount of subsequent new joint damage seen on X-rays (radiographic progression). Another study featured at ACR provided an analysis of radiographic progression in patients with early RA from the Swedish Farmacotherapy (SWEFOT) clinical trial. The Vectra DA test was used to evaluate 220 patients for progression from baseline to Year 1 and from baseline to Year 2. In addition, progression from Year 1 to Year 2 was evaluated for 133 patients who had inadequate initial responses to methotrexate and were treated from month three with the addition of a TNF inhibitor or with triple therapy using methotrexate, sulfasalazine and hydroxychloroquine.
Crescendo Bioscience Announces New Study in the Journal Annals of the Rheumatic Diseases for Vectra DA Blood Test
May 14 14
Crescendo Bioscience announced the online publication of a new study in the journal Annals of the Rheumatic Diseases for Crescendo's Vectra DA blood test. The study is a retrospective analysis of data from the Swedish Farmacotherapy (SWEFOT) clinical trial and shows that Vectra DA is a strong predictor of radiographically visible damage to joints, known as disease progression, in patients newly diagnosed with rheumatoid arthritis (RA). Vectra DA is the only multi-biomarker blood test validated to assess disease activity in patients with rheumatoid arthritis. This study evaluated the Vectra DA test score as a predictor of one-year radiographic progression in 235 patients in SWEFOT. All patients had early rheumatoid arthritis and had not been previously treated with a disease-modifying anti-rheumatic drug (DMARD). The results showed that the Vectra DA score at baseline was an independent predictor of radiographic progression over one year of DMARD treatment. Among the 201 patients with a high Vectra DA score at baseline, 21% had radiographic progression at one year. By contrast, of the 34 patients with a low/moderate Vectra DA score, only 3.4% had radiographic progression at one year, confirming that patients who do not have a high score are at low risk of progression. Vectra DA also effectively differentiated patients with and without disease progression better than the C-reactive protein (CRP) test, and other traditional measures of disease activity, including DAS28-CRP. These findings underscore the clinical value of Vectra DA for predicting disease progression in newly diagnosed patients with RA and its potential to help doctors manage patients based on their risk of disease progression. Importantly, these findings build on earlier results from the Leiden Early Arthritis Cohort study published in Rheumatology (Oxford), which showed that patients with a high Vectra DA score were at a six-fold higher risk of disease progression than those with a low Vectra DA score.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 4, 2014